# Gilead Sciences (GILD) revenue: $29.44B in 2025

URL: https://funkfolio.com/stock/GILD/revenue

> Gilead Sciences (GILD) revenue was $29.44B in fiscal 2025, up 2.4% from fiscal 2024. Over five fiscal years it grew 3.6% a year.

---

## Gilead Sciences (GILD) revenue

**Revenue · fiscal 2025:** $29.44B year ended Dec 31, 2025

Gilead Sciences (GILD) reported revenue of $29.44B in fiscal 2025 (the year ended December 31, 2025). That is 2.4% higher than the $28.75B of fiscal 2024. Figures as of 18 Nov 2026, 12:17 UTC, from the company's filings with the SEC and Yahoo Finance.

### Key facts

- **Revenue, fiscal 2025:** $29.44B
- **Change on fiscal 2024:** +2.4%
- **Growth, 5 years:** +3.6% a year
- **Growth, 10 years:** −1.0% a year
- **Highest on record:** $32.64B fiscal 2015
- **Lowest on record:** $4.23B fiscal 2007
- **Fiscal years on record:** 19 2007–2025

Figures as of 18 Nov 2026, 12:17 UTC. Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

### Gilead Sciences revenue, in more detail

Over the five fiscal years to 2025 revenue grew at a compound 3.6% a year; over ten years the rate was −1.0% a year. Across the 19 fiscal years on record (2007–2025), the highest was $32.64B in fiscal 2015 and the lowest $4.23B in fiscal 2007.

### Revenue by fiscal year

### Gilead Sciences revenue, year by year

Gilead Sciences (GILD) revenue by fiscal year

| Fiscal year | Revenue | Change | Year ended |
| --- | --- | --- | --- |
| 2025 | $29.44B | 2.4% up | Dec 31, 2025 |
| 2024 | $28.75B | 6.0% up | Dec 31, 2024 |
| 2023 | $27.12B | 0.6% down | Dec 31, 2023 |
| 2022 | $27.28B | 0.1% down | Dec 31, 2022 |
| 2021 | $27.31B | 10.6% up | Dec 31, 2021 |
| 2020 | $24.69B | 10.0% up | Dec 31, 2020 |
| 2019 | $22.45B | 1.5% up | Dec 31, 2019 |
| 2018 | $22.13B | 15.2% down | Dec 31, 2018 |
| 2017 | $26.11B | 14.1% down | Dec 31, 2017 |
| 2016 | $30.39B | 6.9% down | Dec 31, 2016 |
| 2015 | $32.64B | 31.1% up | Dec 31, 2015 |
| 2014 | $24.89B | 122.2% up | Dec 31, 2014 |
| 2013 | $11.20B | 15.5% up | Dec 31, 2013 |
| 2012 | $9.70B | 15.7% up | Dec 31, 2012 |
| 2011 | $8.39B | 5.5% up | Dec 31, 2011 |
| 2010 | $7.95B | 13.4% up | Dec 31, 2010 |
| 2009 | $7.01B | 31.4% up | Dec 31, 2009 |
| 2008 | $5.34B | 26.1% up | Dec 31, 2008 |
| 2007 | $4.23B | — | Dec 31, 2007 |

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

### How it is calculated

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

### How to read it

Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.

### Revenue at health care companies of similar size

Revenue of Gilead Sciences and comparable companies

| Company | Revenue | Fiscal year |
| --- | --- | --- |
| [Thermo Fisher Scientific TMO](https://funkfolio.com/stock/TMO/revenue) | $44.56B | 2025 |
| [Amgen AMGN](https://funkfolio.com/stock/AMGN/revenue) | $36.75B | 2025 |
| Gilead Sciences GILD | $29.44B | 2025 |
| [Abbott Laboratories ABT](https://funkfolio.com/stock/ABT/revenue) | $44.33B | 2025 |
| [Novo Nordisk NVO](https://funkfolio.com/stock/NVO/revenue) | DKK 309.06B | 2025 |
| [Pfizer PFE](https://funkfolio.com/stock/PFE/revenue) | $62.58B | 2025 |

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

### Gilead Sciences, figure by figure

- [Gilead Sciences market cap](https://funkfolio.com/stock/GILD/market-cap)
- [Gilead Sciences earnings](https://funkfolio.com/stock/GILD/earnings)
- [Gilead Sciences earnings per share (EPS)](https://funkfolio.com/stock/GILD/eps)
- [Gilead Sciences P/E ratio](https://funkfolio.com/stock/GILD/pe-ratio)
- [Gilead Sciences P/S ratio](https://funkfolio.com/stock/GILD/ps-ratio)
- [Gilead Sciences P/B ratio](https://funkfolio.com/stock/GILD/pb-ratio)
- [Gilead Sciences free cash flow](https://funkfolio.com/stock/GILD/free-cash-flow)
- [Gilead Sciences operating margin](https://funkfolio.com/stock/GILD/operating-margin)
- [Gilead Sciences dividend](https://funkfolio.com/stock/GILD/dividend)
- [Gilead Sciences shares outstanding](https://funkfolio.com/stock/GILD/shares-outstanding)
- [Gilead Sciences total debt](https://funkfolio.com/stock/GILD/total-debt)
- [Gilead Sciences cash on hand](https://funkfolio.com/stock/GILD/cash)
- [Gilead Sciences total assets](https://funkfolio.com/stock/GILD/total-assets)
- [Gilead Sciences return on equity (ROE)](https://funkfolio.com/stock/GILD/roe)
- [Gilead Sciences return on invested capital (ROIC)](https://funkfolio.com/stock/GILD/roic)

[Gilead Sciences (GILD) overview: price, valuation and scorecard](https://funkfolio.com/stock/GILD) [All health care companies by market value](https://funkfolio.com/companies/sector/health-care)

### Gilead Sciences revenue: questions and answers

**What is Gilead Sciences's revenue?**

Gilead Sciences (GILD) reported revenue of $29.44B in fiscal 2025 (the year ended December 31, 2025). That is 2.4% higher than the $28.75B of fiscal 2024.

**What is the growth rate of Gilead Sciences's revenue?**

Over the five fiscal years to 2025 revenue grew at a compound 3.6% a year; over ten years the rate was −1.0% a year.

**What are the highest and lowest revenue figures on record for Gilead Sciences?**

Across the 19 fiscal years on record (2007–2025), the highest was $32.64B in fiscal 2015 and the lowest $4.23B in fiscal 2007.

**How is Gilead Sciences's revenue calculated?**

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For Gilead Sciences it is on record here for 19 fiscal years, 2007 to 2025.

Fiscal years are named for the calendar year they end in.

### Learn: revenue

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Revenue vs earnings vs free cash flow: what each tells you](https://funkfolio.com/learn/stocks/revenue-earnings-free-cash-flow)

  Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.

### Cite this page

Funkfolio, “Gilead Sciences (GILD) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/GILD/revenue

Underlying data: the company's filings with the SEC and Yahoo Finance.
